search
Back to results

Effects of Acupuncture on Body Mass Index in Overweight and Obese Women With Polycystic Ovary Syndrome (PCOS ) (PCOS)

Primary Purpose

PCOS, Overweight, Obesity

Status
Active
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Active acupuncture
Sham acupuncture
Lifestyle management
Sponsored by
Peking University Third Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PCOS focused on measuring PCOS, Overweight, Obesity, Acupuncture, Lifestyle management

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 20 to 40 years
  • BMI≥ 24 to <40
  • PCOS diagnosis according to Rotterdam criteria 2003 with at least two of the following three symptoms: (1) infrequent ovulation or anovulation; (2) hyperandrogenism or clinical manifestations of high blood androgen; (3) ultrasound findings of polycystic ovaries in 1 or 2 ovaries, or ≥12 follicles measuring 2 to 9 mm in diameter, and/or ovarian volume ≥10 mL.

Exclusion Criteria:

  • Exclusion of other endocrine disorders such as androgen secreting tumors, suspected Cushing's syndrome and non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone < 3nmol/L) thyroid dysfunction and hyperprolactinemia.
  • Type I diabetes or not well controlled type II diabetes
  • Pharmacological treatment (cortizone, antidepressant, other antidiabetic treatment such as insulin and acarbose, hormonal contraceptives, hormonal ovulation induction or other drugs judged by discretion of investigator) within 12 weeks. Depo Provera or similar within 6 months.
  • Pregnancy or breastfeeding the last 6 months
  • Acupuncture last 3 months
  • Daily smoking and alcoholic intake

Sites / Locations

  • Peking University Third Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

active acupuncture + lifestyle management

control acupuncture + lifestyle management

Arm Description

Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.

Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.

Outcomes

Primary Outcome Measures

Body mass index (BMI)
PCOS's weight in kilograms divided by the square of her height in meters, reported in kg/m2

Secondary Outcome Measures

total body fat
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
body fat and lean ratio
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
visceral fat
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
basal metabolic rate
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
antral follicle count
examined the ovarian morphology with the B-ultrasound
sex hormone binding globulin (SHBG)
examined with the blood sample
anti-mullerian hormone (AMH)
examined with the blood sample
follicle stimulating hormone (FSH)
examined with the blood sample
luteinizing hormone (LH)
examined with the blood sample
Progestin (P)
examined with the blood sample
Estrogen (E2)
examined with the blood sample
Androgen(T)
examined with the blood sample
Androstenedione (A2)
examined with the blood sample
HOMA-IR
will be assessed during the oral glucose tolerance test (OGTT) , calculation of HOMA-IR: [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5)
HOMA- β
will be assessed during the oral glucose tolerance test (OGTT) ,calculation of HOMA-β: 20 × fasting insulin (mU/mL) / (fasting plasma glucose (mmol/L) - 3.5
glycated hemoglobin ( HbA1c)
The insulin and glucose response in blood
total cholesterol
examined with the blood sample
triglycerides
examined with the blood sample
high density lipoprotein (HDL)
examined with the blood sample
low density lipoprotein (LDL)
examined with the blood sample
lipometabonomic/lipidomics
Detection with the method of metabonomic in blood, the sample size is about 20 participants in each group.
bile acid omics
Detection with the method of metabonomic in blood, the sample size is about 20 participants in each group
β-endorphin
examined with the blood sample
5- hydroxytryptamine (5-HT)
examined with the blood sample
FerrimanGallwey (FG )value
To determine changes in women's hairy with FG rating scale (0-36 score), the higher, the worse.
short form-36 (SF36)
determine the health quality of life by the questionnaire of SF36 (0-100 score), the higher, the better.
EuroQol health index scale (EQ-5D)
determine the health quality of life by the questionnaire of EQ-5D (0-100 score), the higher, the better.
polycystic ovary syndrome questionnaire (PCOSQ);
determine the Effects of PCOS specific symptoms on the participants by the questionnaire of and polycystic ovary syndrome questionnaire (PCOSQ)(26-182 score); the higher, the better.
Self-Rating Anxiety Scale (SAS)
determine the anxiety level with the questionnaire of SAS (20-100 score), the higher, the worse.
Self-Rating Depress Scale (SDS)
determine the depress level with the questionnaire of SDS (20-100 score), the higher, the worse.
Body mass index (BMI)
Weight in kilograms divided by the square of her height in meters, reported in kg/m2
Fibroblast growth factor 19(FGF-19)
examined with the blood sample
Ghrelin
examined with the blood sample
Interleukin 6( IL-6 )
examined with the blood sample
Interleukin 8( IL-8 )
examined with the blood sample
Interleukin 22( IL-22 )
examined with the blood sample
Tumor Necrosis Factor-Alpha (TNF-α)
examined with the blood sample
Gamma-Amino Butyric Acid(GABA)
examined with the blood sample
dopamine(DA)
examined with the blood sample
Glutamate
examined with the blood sample
proteomics
Detection with the Proteomic techniques in blood, the sample size is about 30 participants in each group.
branched-chain amino acids
examined with the blood sample, the sample size is about 30 participants in each group.

Full Information

First Posted
November 6, 2019
Last Updated
September 4, 2023
Sponsor
Peking University Third Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04193371
Brief Title
Effects of Acupuncture on Body Mass Index in Overweight and Obese Women With Polycystic Ovary Syndrome (PCOS )
Acronym
PCOS
Official Title
Department of Traditional Chinese Medicine (TCM), Peking University Third Hospital, Beijing, China
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 6, 2019 (Actual)
Primary Completion Date
September 1, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking University Third Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a cross-sectional case-control study combined with a randomised controlled trial (RCT) study. This study aims to compare the effect of acupuncture, with usual care (lifestyle management) for weight control, with BMI (Body Mass index) as main outcome along with improvement of reproductive and metabolic dysfunction in overweight and obese women with PCOS, and further exploring the alteration of lipidomics, bile acid omics, proteomics and branched-chain amino acids between PCOS and the normal controls, and before and after the acupuncture treatment in different gourps.
Detailed Description
Polycystic ovary syndrome (PCOS) affects 6 to 18% of all women and is the most common female endocrine and metabolic disorder during the reproductive years. PCOS is characterized by anovulation, hyperandrogenism and metabolic dysfunction.Obesity is ~40% higher in women with PCOS than in healthy women. Overweight results in irregular cycles, insulin resistance and infertility. Acupuncture is assumed to reduce weight The overall hypothesis is that if the Body mass index (BMI) decreased, ovulation can be induced, hyperandrogenism decreased, and insulin sensitivity improved in these women. Although several treatment strategies have shown efficacy, importantly, there is a need for Comparative Effectiveness Research (CER) to strengthen the evidence base for clinical and policy decision-making. Therefore, the investigators aim to compare the effect of acupuncture, with usual care (lifestyle management) for weight loss, and improvement and prevention of reproductive and metabolic dysfunction in overweight and obese women with PCOS. We further compare the differences of PCOS and the controls with the methods of lipidomics, bile acid omics, proteomics and branched-chain amino acids, exploring the mechanisms of acupuncture on PCOS with this kind of methods.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PCOS, Overweight, Obesity
Keywords
PCOS, Overweight, Obesity, Acupuncture, Lifestyle management

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a cross-sectional case-control part and an open-labelled RCT with a comparative effectiveness design. The inter-ventions to be tested are (1) acupuncture during 4 months+lifestylemanagement; (3) sham acupuncture+lifestyle management
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
106 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
active acupuncture + lifestyle management
Arm Type
Experimental
Arm Description
Participants in this group are treated by active acupuncture and lifestyle management for 4 months and follow up 4 months after the last treatment.
Arm Title
control acupuncture + lifestyle management
Arm Type
Sham Comparator
Arm Description
Participants in this group are treated by control acupuncture and lifestyle management for four months and follow up 4 months after the last treatment.
Intervention Type
Other
Intervention Name(s)
Active acupuncture
Intervention Description
The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
Intervention Type
Other
Intervention Name(s)
Sham acupuncture
Intervention Description
In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
Intervention Type
Other
Intervention Name(s)
Lifestyle management
Intervention Description
All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9). All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week.
Primary Outcome Measure Information:
Title
Body mass index (BMI)
Description
PCOS's weight in kilograms divided by the square of her height in meters, reported in kg/m2
Time Frame
After 4 months of intervention;
Secondary Outcome Measure Information:
Title
total body fat
Description
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
body fat and lean ratio
Description
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
visceral fat
Description
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
basal metabolic rate
Description
examined with a body composition analyzer (Tanita Corporation, model MC-180, Japan) .
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
antral follicle count
Description
examined the ovarian morphology with the B-ultrasound
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
sex hormone binding globulin (SHBG)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
anti-mullerian hormone (AMH)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
follicle stimulating hormone (FSH)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
luteinizing hormone (LH)
Description
examined with the blood sample
Time Frame
After 4 months of intervention Follow-up 4 months after last treatment.,
Title
Progestin (P)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Estrogen (E2)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Androgen(T)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Androstenedione (A2)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
HOMA-IR
Description
will be assessed during the oral glucose tolerance test (OGTT) , calculation of HOMA-IR: [fasting insulin (μU/mL) × fasting glucose (mmol/L)] / 22.5)
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
HOMA- β
Description
will be assessed during the oral glucose tolerance test (OGTT) ,calculation of HOMA-β: 20 × fasting insulin (mU/mL) / (fasting plasma glucose (mmol/L) - 3.5
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
glycated hemoglobin ( HbA1c)
Description
The insulin and glucose response in blood
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
total cholesterol
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
triglycerides
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
high density lipoprotein (HDL)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
low density lipoprotein (LDL)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
lipometabonomic/lipidomics
Description
Detection with the method of metabonomic in blood, the sample size is about 20 participants in each group.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
bile acid omics
Description
Detection with the method of metabonomic in blood, the sample size is about 20 participants in each group
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
β-endorphin
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
5- hydroxytryptamine (5-HT)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
FerrimanGallwey (FG )value
Description
To determine changes in women's hairy with FG rating scale (0-36 score), the higher, the worse.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
short form-36 (SF36)
Description
determine the health quality of life by the questionnaire of SF36 (0-100 score), the higher, the better.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
EuroQol health index scale (EQ-5D)
Description
determine the health quality of life by the questionnaire of EQ-5D (0-100 score), the higher, the better.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
polycystic ovary syndrome questionnaire (PCOSQ);
Description
determine the Effects of PCOS specific symptoms on the participants by the questionnaire of and polycystic ovary syndrome questionnaire (PCOSQ)(26-182 score); the higher, the better.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Self-Rating Anxiety Scale (SAS)
Description
determine the anxiety level with the questionnaire of SAS (20-100 score), the higher, the worse.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Self-Rating Depress Scale (SDS)
Description
determine the depress level with the questionnaire of SDS (20-100 score), the higher, the worse.
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Body mass index (BMI)
Description
Weight in kilograms divided by the square of her height in meters, reported in kg/m2
Time Frame
Follow-up 4 months after last treatment.
Title
Fibroblast growth factor 19(FGF-19)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Ghrelin
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Interleukin 6( IL-6 )
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Interleukin 8( IL-8 )
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Interleukin 22( IL-22 )
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Tumor Necrosis Factor-Alpha (TNF-α)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Gamma-Amino Butyric Acid(GABA)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
dopamine(DA)
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
Glutamate
Description
examined with the blood sample
Time Frame
After 4 months of intervention, Follow-up 4 months after last treatment.
Title
proteomics
Description
Detection with the Proteomic techniques in blood, the sample size is about 30 participants in each group.
Time Frame
After 4 months of intervention
Title
branched-chain amino acids
Description
examined with the blood sample, the sample size is about 30 participants in each group.
Time Frame
After 4 months of intervention

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
No, the enrollment is based on biological sex
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: PCOS Age 20 to 40 years BMI≥ 24 to <40 PCOS diagnosis according to Rotterdam criteria 2003 with at least two of the following three symptoms: (1) infrequent ovulation or anovulation; (2) hyperandrogenism or clinical manifestations of high blood androgen; (3) ultrasound findings of polycystic ovaries in 1 or 2 ovaries, or ≥12 follicles measuring 2 to 9 mm in diameter, and/or ovarian volume ≥10 mL. Inclusion criteria: Controls Controls should have BMI>25to<40, regular cycles with 28 days±2 days and no signs of hyperandrogenism and PCO morphology on ultrasound Exclusion Criteria: Exclusion of other endocrine disorders such as androgen secreting tumors, suspected Cushing's syndrome and non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone < 3nmol/L) thyroid dysfunction and hyperprolactinemia. Type I diabetes or not well controlled type II diabetes Pharmacological treatment (cortizone, antidepressant, other antidiabetic treatment such as insulin and acarbose, hormonal contraceptives, hormonal ovulation induction or other drugs judged by discretion of investigator) within 12 weeks. Depo Provera or similar within 6 months. Pregnancy or breastfeeding the last 6 months Acupuncture last 3 months Daily smoking and alcoholic intake
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
haolin zhang
Organizational Affiliation
Peking University Third Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100191
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Effects of Acupuncture on Body Mass Index in Overweight and Obese Women With Polycystic Ovary Syndrome (PCOS )

We'll reach out to this number within 24 hrs